CS
ELVN icon

Credit Suisse’s Enliven Therapeutics ELVN Stock Holding History

Credit Suisse’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$385K Hold
21,895
– – ﹤0.01% 2746
2023
Q4 		$303K Sell
21,895
-955
-4% -$11.7K ﹤0.01% 2911
2023
Q3 		$312K Sell
22,850
-1,205
-5% -$20.3K ﹤0.01% 2921
2023
Q2 		$491K Buy
+24,055
New +$486K ﹤0.01% 2789

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Credit Suisse's ELVN Position: Q1 2024 in Review

Credit Suisse held its Enliven Therapeutics (ELVN) position steady in Q1 2024 at 21,895 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Credit Suisse first reported a position in ELVN in Q2 2023 and has held it in 4 quarters since. The position peaked at $491K in Q2 2023. 74 funds tracked by Wall St. Rank hold ELVN as of Q1 2024.

  • Credit Suisse held 21,895 shares of Enliven Therapeutics worth $385K as of Q1 2024.
  • Credit Suisse left its Enliven Therapeutics share count unchanged in Q1 2024.
  • Enliven Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2746 holding.
  • Credit Suisse first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Credit Suisse's Enliven Therapeutics position peaked at $491K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.